Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Virpax Pharmaceuticals, Inc. (VRPX)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Cost of goods sold | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross profit | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Research and development | 37.0% | 42.4% | 45.3% | 34.1% | 35.6% | 28.7% | 21.8% | |
| General and administrative | 65.6% | 59.8% | 56.9% | 40.2% | 34.6% | 37.3% | 40.2% | |
| EBIT | -105.5% | -104.5% | -104.1% | -68.4% | -63.4% | -57.8% | -52.0% | |
| Pre-tax income | -100.1% | -100.5% | -101.1% | -69.7% | -65.0% | -59.9% | -54.4% | |
| Income taxes | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -100.1% | -100.5% | -101.1% | -69.7% | -65.0% | -59.9% | -54.4% | |
|